Suppr超能文献

俄罗斯中部人群中参与多基因检测的乳腺癌患者和健康供体的高风险和中度风险变异

High- and Moderate-Risk Variants Among Breast Cancer Patients and Healthy Donors Enrolled in Multigene Panel Testing in a Population of Central Russia.

作者信息

Shumilova Syuykum, Danishevich Anastasia, Nikolaev Sergey, Krasnov George, Ikonnikova Anna, Isaeva Darya, Surzhikov Sergei, Zasedatelev Alexander, Bodunova Natalia, Nasedkina Tatiana

机构信息

Engelhardt Institute of Molecular Biology, the Russian Academy of Sciences, 119991 Moscow, Russia.

SBHI Moscow Clinical Scientific Center named after Loginov of Moscow Healthcare Department, 111123 Moscow, Russia.

出版信息

Int J Mol Sci. 2024 Nov 25;25(23):12640. doi: 10.3390/ijms252312640.

Abstract

Assessments of breast cancer (BC) risk in carriers of pathogenic variants identified by gene panel testing in different populations are highly in demand worldwide. We performed target sequencing of 78 genes involved in DNA repair in 860 females with BC and 520 age- and family history-matched controls from Central Russia. Among BC patients, 562/860 (65.3%) were aged 50 years or less at the time of diagnosis. In total, 190/860 (22%) BC patients were carriers of 198 pathogenic/likely pathogenic (P/LP) variants in 30 genes, while among controls, 32/520 (6.2%) carriers of P/LP variants in 17 genes were identified. The odds ratio [95% confidence interval] was 16.3 [4.0-66.7] for ; 12.0 [2.9-45.9] for ; and 7.3 [0.9-56.7] for ( < 0.05). Previously undescribed and variants, as well as novel recurrent mutations, were identified. The contribution to BC susceptibility of truncating variants in the genes , , , (p. E1155*), and (p. P32fs) was evaluated. The , , and genes did not demonstrate associations with BC risk. Finding deleterious mutations in BC patients is important for diagnosis and management; in controls, it opens up the possibility of prevention and early diagnostics.

摘要

在全球范围内,对于通过基因检测面板在不同人群中鉴定出的致病基因变异携带者进行乳腺癌(BC)风险评估的需求非常高。我们对来自俄罗斯中部的860名乳腺癌女性患者和520名年龄及家族史匹配的对照者进行了涉及DNA修复的78个基因的靶向测序。在乳腺癌患者中,562/860(65.3%)在诊断时年龄为50岁或以下。总共,190/860(22%)的乳腺癌患者是30个基因中198个致病/可能致病(P/LP)变异的携带者,而在对照者中,鉴定出17个基因中P/LP变异的携带者为32/520(6.2%)。[95%置信区间]的优势比对于 为16.3[4.0 - 66.7];对于 为12.0[2.9 - 45.9];对于 为7.3[0.9 - 56.7](<0.05)。鉴定出了先前未描述的 和 变异以及新的复发性突变。评估了基因 、 、 、 (p.E1155*)和 (p.P32fs)中截短变异对乳腺癌易感性的贡献。 、 和 基因未显示与乳腺癌风险相关。在乳腺癌患者中发现有害突变对于诊断和管理很重要;在对照者中,这为预防和早期诊断开辟了可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96b2/11641773/c740909b1e4d/ijms-25-12640-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验